CSPC Innovation Pharmaceutical Co., Ltd. (SHE:300765)
China
· Delayed Price · Currency is CNY 37.16
+0.47 (1.28%)
Mar 28, 2025, 2:45 PM CST
SHE:300765 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 1,928 | 2,485 | 2,571 | 1,790 | 1,289 | Upgrade
|
| Other Revenue | 52.64 | 53.66 | 55.25 | 60.14 | 28.2 | Upgrade
|
| Revenue | 1,981 | 2,539 | 2,626 | 1,850 | 1,317 | Upgrade
|
| Revenue Growth (YoY) | -21.98% | -3.34% | 42.00% | 40.40% | 4.85% | Upgrade
|
| Cost of Revenue | 1,155 | 1,383 | 1,493 | 1,043 | 584.91 | Upgrade
|
| Gross Profit | 825.52 | 1,155 | 1,133 | 807.09 | 732.5 | Upgrade
|
| Selling, General & Admin | 233.37 | 302.21 | 312.29 | 323.91 | 374.09 | Upgrade
|
| Research & Development | 842.2 | 671.4 | 46.3 | 26.5 | 14.05 | Upgrade
|
| Other Operating Expenses | 29.57 | 32.73 | 19.92 | 15.75 | 1.63 | Upgrade
|
| Operating Expenses | 1,102 | 1,001 | 386.31 | 372.19 | 388.36 | Upgrade
|
| Operating Income | -276.66 | 153.8 | 747.14 | 434.9 | 344.14 | Upgrade
|
| Interest Expense | -6.37 | -17.63 | -0.22 | -2.83 | - | Upgrade
|
| Interest & Investment Income | 42.21 | 85.92 | 49.57 | 45.37 | 34.02 | Upgrade
|
| Currency Exchange Gain (Loss) | 7.44 | 25.17 | 55.21 | -7.07 | -19.66 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.44 | 1.4 | -0.98 | -1.08 | 5.21 | Upgrade
|
| EBT Excluding Unusual Items | -233.83 | 248.65 | 850.72 | 469.29 | 363.71 | Upgrade
|
| Impairment of Goodwill | - | - | - | -3.47 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.89 | - | - | 3.59 | 1.94 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.71 | 0.33 | 1.61 | 0.38 | -0.43 | Upgrade
|
| Asset Writedown | -3.1 | -2.15 | -6.17 | -10.1 | - | Upgrade
|
| Other Unusual Items | 15.8 | 15.15 | 5.22 | 18.3 | - | Upgrade
|
| Pretax Income | -221.3 | 262.14 | 851.37 | 477.99 | 365.22 | Upgrade
|
| Income Tax Expense | 81.91 | 136.47 | 124.76 | 85.29 | 65.51 | Upgrade
|
| Earnings From Continuing Operations | -303.21 | 125.67 | 726.61 | 392.7 | 299.71 | Upgrade
|
| Minority Interest in Earnings | 356.94 | 308.77 | -0.33 | 0.53 | 0.12 | Upgrade
|
| Net Income | 53.73 | 434.44 | 726.28 | 393.23 | 299.84 | Upgrade
|
| Net Income to Common | 53.73 | 434.44 | 726.28 | 393.23 | 299.84 | Upgrade
|
| Net Income Growth | -87.63% | -40.18% | 84.70% | 31.15% | 9.75% | Upgrade
|
| Shares Outstanding (Basic) | 1,399 | 1,397 | 1,337 | 1,337 | 1,178 | Upgrade
|
| Shares Outstanding (Diluted) | 1,399 | 1,397 | 1,337 | 1,337 | 1,178 | Upgrade
|
| Shares Change (YoY) | 0.16% | 4.50% | -0.02% | 13.53% | 6.56% | Upgrade
|
| EPS (Basic) | 0.04 | 0.31 | 0.54 | 0.29 | 0.25 | Upgrade
|
| EPS (Diluted) | 0.04 | 0.31 | 0.54 | 0.29 | 0.25 | Upgrade
|
| EPS Growth | -87.65% | -42.76% | 84.73% | 15.52% | 2.99% | Upgrade
|
| Free Cash Flow | -1,713 | 139.72 | 526.67 | 96.67 | 231.33 | Upgrade
|
| Free Cash Flow Per Share | -1.22 | 0.10 | 0.39 | 0.07 | 0.20 | Upgrade
|
| Dividend Per Share | 0.020 | 0.267 | 0.069 | 0.069 | 0.036 | Upgrade
|
| Dividend Growth | -92.50% | 284.29% | - | 94.94% | 49.58% | Upgrade
|
| Gross Margin | 41.68% | 45.51% | 43.15% | 43.63% | 55.60% | Upgrade
|
| Operating Margin | -13.97% | 6.06% | 28.45% | 23.51% | 26.12% | Upgrade
|
| Profit Margin | 2.71% | 17.11% | 27.65% | 21.26% | 22.76% | Upgrade
|
| Free Cash Flow Margin | -86.47% | 5.50% | 20.05% | 5.23% | 17.56% | Upgrade
|
| EBITDA | -60.39 | 308.55 | 819.26 | 504.05 | 397.56 | Upgrade
|
| EBITDA Margin | -3.05% | 12.15% | 31.19% | 27.25% | 30.18% | Upgrade
|
| D&A For EBITDA | 216.27 | 154.76 | 72.12 | 69.15 | 53.42 | Upgrade
|
| EBIT | -276.66 | 153.8 | 747.14 | 434.9 | 344.14 | Upgrade
|
| EBIT Margin | -13.97% | 6.06% | 28.45% | 23.51% | 26.12% | Upgrade
|
| Effective Tax Rate | - | 52.06% | 14.65% | 17.84% | 17.94% | Upgrade
|
| Revenue as Reported | 1,981 | 2,539 | 2,626 | 1,850 | 1,317 | Upgrade
|
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.